<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01702194</url>
  </required_header>
  <id_info>
    <org_study_id>0087</org_study_id>
    <nct_id>NCT01702194</nct_id>
  </id_info>
  <brief_title>TD-1211 IV/Oral Mass Balance Study</brief_title>
  <official_title>A Single-Dose, Fixed-Sequence, Two-Period, Two−Treatment Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD−1211 Following an Intravenous Infusion and an Oral Dose of [14C]TD−1211 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine TD-1211 is processed by the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will provide information regarding the metabolic pathway of TD 1211, the need for
      evaluation of potential drug-drug interactions, the need for studies in special populations
      and the absolute oral bioavailability of TD-1211. The administration of radiolabeled drug is
      necessary to fully characterize the rates and routes of elimination of TD 1211, providing
      further quantitative information on the disposition of TD 1211. The results from this study
      will allow a more comprehensive comparison between animal and human routes of elimination and
      metabolic profiles of TD 1211.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>0 to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>0 to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak plasma concentration (Tmax)</measure>
    <time_frame>0 to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T 1/2)</measure>
    <time_frame>0 to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent total recovery of radioactivity in blood, urine, and feces</measure>
    <time_frame>0 to 312 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>OIC</condition>
  <arm_group>
    <arm_group_label>TD-1211 IV [C14]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1211 IV [C14]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 PO [C14]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1211 PO [C14]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211 IV [C14]</intervention_name>
    <arm_group_label>TD-1211 IV [C14]</arm_group_label>
    <other_name>TD-1211</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211 PO [C14]</intervention_name>
    <arm_group_label>TD-1211 PO [C14]</arm_group_label>
    <other_name>TD-1211</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy, nonsmoking male, 18 to 50 years old, inclusive.

          2. Agrees to use a highly effective method of birth control.

          3. Body mass index (BMI) 19 to 30 kg/m2, inclusive, and weighs at least 55 kg.

          4. Willing and able to give written informed consent.

        Exclusion Criteria:

          1. Evidence or history of clinically significant allergic (except for untreated,
             asymptomatic, seasonal allergies at time of dosing), hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological
             disease.

          2. Hemoglobin &lt;14.1 g/dL or hematocrit &lt; 40.6% at Screening.

          3. History of hypersensitivity to drugs, or a history of or any current clinically
             significant hypersensitivities.

          4. Any condition possibly affecting drug absorption (e.g., previous surgery on the
             gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall
             bladder, or pancreas]).

          5. Participated in another clinical trial of an investigational drug (or medical device)
             within 60 days (or 5 half-lives of the investigational drug, whichever is longer)
             prior to Screening, or is currently participating in another trial of an
             investigational drug (or medical device).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>October 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2012</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OIC</keyword>
  <keyword>Opioid Induced Constipation</keyword>
  <keyword>Constipation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

